We are writing to provide an update on the appraisal of erenumab for migraine.
A high volume of comments have been received in response to the appraisal consultation document. Given this and the importance of ensuring that NICE and the committee have adequate time to fully consider these comments, and where necessary engage with appropriate experts, we have taken the decision to reschedule the discussion of this appraisal.
I would like to reassure you that this decision has not been taken lightly. It has been done to ensure that the committee can make the most informed and robust decision for this technology for patients with migraine. NICE has rescheduled the committee meeting to 16 April 2019 (previously scheduled for 14 February 2019).